RAF1 and neoplasm: On the one hand, sorafenib inhibits the receptor tyrosine kinases c-Kit and Flt-3 6 and the serine/threonine kinases, including Raf kinases involved in the Raf/MEK/ERK pathway 7, which leads to inhibition of tumor-cell proliferation.